Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 20Terminated 4Active not recruiting 4Withdrawn 3Recruiting 3No longer available 3Unknown 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1

Conditions

Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Leukemia 1Blast Crisis 1

Interventions

pembrolizumab 567Specimen Handling 487Carboplatin 456Magnetic Resonance Spectroscopy 442Cyclophosphamide 418Cisplatin 412Radiotherapy 353Gemcitabine 318Bevacizumab 317Paclitaxel 304Biopsy 291Drug Therapy 286Blood Specimen Collection 249Capecitabine 244Oxaliplatin 242fludarabine 238Nivolumab 236venetoclax 227Injections 214Docetaxel 209Fluorouracil 204Dexamethasone 187Radiosurgery 182Rituximab 162Pemetrexed 160Standard of Care 156Surgical Procedures, Operative 148durvalumab 146atezolizumab 146tislelizumab 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × midostaurin × Clear all
NCT02115295 2026-05-20

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
508 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT06313437 2026-03-25

Revumenib in Combination With 7+3 + Midostaurin in AML

Dana-Farber Cancer Institute

Phase 1 Recruiting
22 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT04385290 2025-09-08

MOSAIC

Technische Universität Dresden

Phase 1/2 Recruiting
214 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡